AMPHASTAR PHARMACEUTICALS INC (AMPH) competitors & alternatives
Health Care · NASDAQ
AMPHASTAR PHARMACEUTICALS INC (AMPH)'s top competitors and alternatives — its most similar public companies — include Baxter International (BAX), West Pharmaceutical Services (WST), AMNEAL PHARMACEUTICALS INC CLASS A (AMRX), LIQUIDIA CORP (LQDA), United Therapeutics (UTHR), LIGAND PHARMACEUTICALS INC (LGND), AQUESTIVE THERAPEUTICS INC (AQST), XERIS BIOPHARMA HOLDINGS INC (XERS), THERAVANCE BIOPHARMA INC (TBPH), Viatris (VTRS), INNOVIVA INC (INVA) and NUVECTIS PHARMA INC (NVCT). These are AMPHASTAR PHARMACEUTICALS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top AMPH competitors & alternatives
-
Baxter InternationalBAXHealth Care
A diversified healthcare company producing sterile IV solutions, infusion systems, parenteral nutrition, inhaled anesthetics, surgical sealants, smart beds,…
$21.74 (as of 2026-07-22) · market cap $11.5B
-
West Pharmaceutical ServicesWSTHealth Care
Global leader in injectable drug containment and delivery systems serving biopharmaceutical and medical device manufacturers with primary packaging, drug…
$358.41 (as of 2026-07-22) · market cap $25.8B
-
AMNEAL PHARMACEUTICALS INC CLASS AAMRXHealth Care
Amneal Pharmaceuticals is a diversified biopharma company providing a broad range of essential, affordable generic and specialty medicines, alongside…
$17.75 (as of 2026-07-22) · market cap $5.7B
-
LIQUIDIA CORPLQDAHealth Care
Liquidia is a rare-disease biopharmaceutical company commercializing YUTREPIA, a next-generation inhaled treprostinil with proprietary particle engineering,…
$87.04 (as of 2026-07-22) · market cap $7.7B
-
United TherapeuticsUTHRHealth Care
United Therapeutics is a rare disease specialist dominating pulmonary hypertension treatment through multiple treprostinil delivery formats while pursuing…
$527.07 (as of 2026-07-22) · market cap $22.7B
-
LIGAND PHARMACEUTICALS INCLGNDHealth Care
Ligand Pharmaceuticals is a biotechnology firm that generates recurring revenue through royalty interests and the licensing of proprietary drug formulation…
$304.26 (as of 2026-07-22) · market cap $6.1B
-
AQUESTIVE THERAPEUTICS INCAQSTHealth Care
Aquestive develops orally disintegrating film formulations for CNS disorders, acute seizures, and opioid use, leveraging proprietary sublingual and buccal film…
$3.94 (as of 2026-07-22) · market cap $496M
-
XERIS BIOPHARMA HOLDINGS INCXERSHealth Care
A commercial-stage biopharma company with three FDA-approved therapies for rare endocrine and neurological diseases and a proprietary injectable drug…
$8.38 (as of 2026-07-22) · market cap $1.5B
-
THERAVANCE BIOPHARMA INCTBPHHealth Care
A commercial-stage biopharmaceutical company with an FDA-approved COPD inhalation therapy under review for strategic alternatives following a failed neurology…
$16.81 (as of 2026-07-22) · market cap $873M
-
ViatrisVTRSHealth Care
A global pharmaceutical giant supplying over 1 billion patients annually with generics, branded medicines, and an expanding innovative pipeline across more…
$17.01 (as of 2026-07-22) · market cap $20.0B
-
INNOVIVA INCINVAHealth Care
A diversified biopharmaceutical company combining respiratory royalties from GSK blockbusters (BREO, ANORO) with a growing critical care and infectious disease…
$21.43 (as of 2026-07-22) · market cap $1.6B
-
NUVECTIS PHARMA INCNVCTHealth Care
Nuvectis is an early-stage oncology biotech developing NXP900, a novel SRC/YES1 kinase inhibitor designed to overcome drug resistance in solid tumors including…
$19.29 (as of 2026-07-22) · market cap $608M
Not quite? Describe exactly what you want →
Peers are AMPHASTAR PHARMACEUTICALS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: AMPHASTAR PHARMACEUTICALS INC (AMPH).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.